Life Sciences

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
15 March 2024

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

The company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, reflects enthusiasm for Siolta's...

Read more
STARFISH Bioscience Raises €900,000 From Seventure Partners To Regenerate Soil Microbiomes By Developing The Next Generation Of Microbial Biostimulants For Sustainable Agriculture
6 February 2024

STARFISH Bioscience Raises €900,000 From Seventure Partners To Regenerate Soil Microbiomes By Developing The Next Generation Of Microbial Biostimulants For Sustainable Agriculture

Starfish Bioscience today announced that it has raised €900,000 from Seventure Partners, the world's leading investor in the microbiome field through its Health for Life...

Read the press release
Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines
5 December 2023

Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful...

Read more
Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.
26 October 2023

Pharma announces positive outcome following DSMB review reinforcing confidence in phase 3 on-going trial.

Maat Pharma announces that the DSMB unanimoulsy recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host Disease...

Read the press release
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
26 October 2023

MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013

MaaT Pharma today announced that the DSMB unanimously recommended that the open-label, single arm pivotal Phase 3 clinical trial evaluating MaaT013 in acute Graft-versus-Host...

Read more
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
30 June 2023

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

Enterome today announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of...

Read the press release
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
14 June 2023

Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...

Read the press release
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
9 May 2023

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships between VE303 bacterial species and multiple parameters that...

Read the press release
Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors
9 May 2023

Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, announces the...

Read the press release